
FundingHealthcare & Life Sciences
RISA Labs raises $11.1M Series A for oncology AI
By Abha Lohia · Editor ·
Series APalo AltoFounded June 2024
- RISA Labs builds an AI operating system that automates administrative tasks for cancer care
- It raised $11.1M in Series A co-led by Cencora Ventures and Optum Ventures
- The platform freed up 80% of admin staff time at one partner site and cut denials by 40%
What happened
- RISA Labs has closed an $11.1M Series A funding round.
- The round was co-led by Cencora Ventures and Optum Ventures.
- Oncology Ventures, Z21 Ventures, and John Simon (via Ventureforgood) also participated.
- The company builds an AI operating system for oncology that automates patient access, benefits verification, and prior authorization.
- Its product, BOSS Console, acts as a command control panel for cancer clinics and health systems.
- The platform connects to EMR, payer, and benefits systems and uses AI agents to read, reason, and act across them.
- Funds will be used to accelerate deployment across US cancer clinics, health systems, specialty pharmacies, and infusion networks.
Why it matters
- Healthtech was among the top 10 funded sectors in the Indian startup ecosystem in 2025, with over $700M across 54 deals.
- RISA Labs previously raised a $3.5M seed round led by Flipkart co-founder Binny Bansal in April 2025.
- The company was founded in June 2024 and is headquartered in Palo Alto, California.
The business
- RISA Labs provides an AI operating system for oncology that automates administrative workflows.
- Its BOSS Console is a command control panel for mission-critical institutions like cancer clinics and health systems.
- The platform connects to EMR, payer, and benefits systems and other systems of record.
- AI agents read, reason, and act across systems, adapting in real time to changing forms, rules, and interfaces.
- Target customers are cancer clinics, health systems, specialty pharmacies, and infusion networks in the US.
- At one partner site, the platform freed up ~80% of administrative staff time, reduced denials by up to 40%, and achieved a 97.8% first-pass approval rate.
- Patient authorizations are filed within 24 hours of request, on track to drop below 2 hours from an average 8-day backlog.
- In nine months, partner institutions expanded from initial deployment to second and third workflows.
The founders
KJ
Kshitij Jaggi
CEO- Kshitij Jaggi is the CEO of RISA Labs.
- He is an IIT Kanpur alumnus.
- He co-founded healthcare startup Urban Health.
KS
Kumar Shivang
CTO- Kumar Shivang is the CTO of RISA Labs.
- He is an IIT Kanpur alumnus.
- He co-founded healthcare startup Urban Health.
Who put in money
- Cencora Ventures co-lead — Corporate venture capital fund of Cencora.
- Optum Ventures co-lead
- Oncology Ventures participated
- Z21 Ventures participated
- John Simon participated — Co-founder of General Catalyst, investing via Ventureforgood entity.
- Binny Bansal existing — Flipkart co-founder, led the seed round and continued backing in Series A.
In numbers
~80%Administrative staff time freed up
up to 40%Denials reduced
97.8%First-pass approval rate
within 24 hoursPatient authorization filing time
more than 20FTEs repurposed at one partner site
$3.5MSeed round amount · 2025
What happens next
- Accelerate deployment across US cancer clinics, health systems, specialty pharmacies, and infusion networks.
- Go deeper in oncology, partner with ecosystem leaders, and expand AI-driven workflows across the full continuum of cancer care.
- Extend capabilities to specialty pharmacy operations via the BOSS Console.
Earlier rounds
- April 2025 · Seed · $3.5M · led by Binny Bansal
Words to know
- Series A
- The first significant round of venture capital funding, typically used to scale the business.
- EMR
- Electronic Medical Record – a digital version of a patient's medical history.
- Prior authorization
- Approval from a health insurance plan before a medical service or prescription is provided.
- FTE
- Full-Time Equivalent – a unit that indicates the workload of an employed person.
The numbers around it
Healthcare & Life Sciences in January 2026: 12 rounds with a disclosed amount, $99.0 million in all; the biggest was Sukino ($31M). Every sector this year →
Other articles talking about it
TMCnet ↗The Economic Times ↗Inc42 ↗indian-startup-times ↗Indian Startup Times ↗thesaasnews ↗Entrackr ↗Inc42 ↗Entrackr ↗
Terms in this story
- Funding stage: Startups raise money in steps called funding stages: pre-seed, seed, Series A, B, C and later, ending in a listing or a sale. Each step is larger and asks for more proof. In India, Series A rounds run from a few million dollars to about $15 million, as of November 2026.
- Series A: Series A is usually the first large round a startup raises from venture capital funds, after it has shown that people want what it sells. In India it commonly runs from a few million dollars to about $15 million, or roughly ₹25 crore to over ₹100 crore, with founders selling about 15 to 25 percent, as of November 2026.
- Lead investor: A lead investor is the investor that sets the price and main terms of a funding round, does the deepest checks on the company and usually puts in the largest cheque. When a headline says a round was led by a fund, that fund was the first to commit and shaped the deal that others joined.
Read next
FundingAugust AI raises $12M for US expansionAugust AI offers an AI health assistant that answers medical questions through WhatsApp and a mobile appFundingVitusCare raises $3 million Series BVitusCare runs dialysis units inside partner hospitals, which keeps costs low, and has grown from 22 to over 60 centresLaunchKapiva gives away Dia Free Juice on World Diabetes DayKapiva is a Bengaluru-based Ayurveda wellness brand selling herbal juices and supplements, with a flagship juice aimed at people managing blood sugar
All startup news on 14 January 2026 →
Is this RISA Labs? Get your “Featured on StopDown” badge →